(Q45377033)

English

Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern

scientific article published in March 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

13 December 2017

Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern (English)

1 reference

Europe PubMed Central

13 December 2017

Hepatitis B virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

8

1 reference

Europe PubMed Central

13 December 2017

author name string

J Inoue

1

1 reference

Europe PubMed Central

13 December 2017

Y Ueno

2

1 reference

Europe PubMed Central

13 December 2017

Y Wakui

3

1 reference

Europe PubMed Central

13 December 2017

H Niitsuma

4

1 reference

Europe PubMed Central

13 December 2017

K Fukushima

5

1 reference

Europe PubMed Central

13 December 2017

Y Yamagiwa

6

1 reference

Europe PubMed Central

13 December 2017

M Shiina

7

1 reference

Europe PubMed Central

13 December 2017

E Kakazu

9

1 reference

Europe PubMed Central

13 December 2017

K Tamai

10

1 reference

Europe PubMed Central

13 December 2017

N Obara

11

1 reference

Europe PubMed Central

13 December 2017

T Iwasaki

12

1 reference

Europe PubMed Central

13 December 2017

T Shimosegawa

13

1 reference

Europe PubMed Central

13 December 2017

publication date

1 March 2011

1 reference

Europe PubMed Central

13 December 2017

Journal of Viral Hepatitis

1 reference

Europe PubMed Central

13 December 2017

18

1 reference

Europe PubMed Central

13 December 2017

3

1 reference

Europe PubMed Central

13 December 2017

206-215

1 reference

Europe PubMed Central

13 December 2017

Hepatitis B virus infection--natural history and clinical consequences

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

Hepatitis B virus resistance to antivirals: clinical implications and management.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

Hepatitis B Virus Infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

Therapeutic strategies in the management of patients with chronic hepatitis B virus infection.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

Long-term therapy of chronic hepatitis B with lamivudine.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

Virologic response and resistance to adefovir in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

Viral features of lamivudine resistant hepatitis B genotypes A and D.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

HBV drug resistance: mechanisms, detection and interpretation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients with liver cirrhosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

Chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

Enhanced intracellular retention of a hepatitis B virus strain associated with fulminant hepatitis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01301.X

21 January 2018

Identifiers

10.1111/J.1365-2893.2010.01301.X

1 reference

Europe PubMed Central

13 December 2017

1 reference

Europe PubMed Central

13 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45377033&oldid=2076256304"